Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06450171 · ClinicalTrials.gov registry record · NA

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study

A NA study of Cancer Predisposition Syndrome and Predisposition, Genetic, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
1,000
Enrollment target
1
Study location

NCT06450171 is a NA study of Cancer Predisposition Syndrome and Predisposition, Genetic that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 1,000 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06450171, a NA study of Cancer Predisposition Syndrome and Predisposition, Genetic, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
1,000 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to evaluate the possible benefits and harms of screening with an investigational blood test designed to detect many types of cancer early. The name of the screening blood test being studied is: -GRAIL Galleri test

Interventions

  • OTHER GRAIL Galleri Test

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2024-09-27
Est. Completion 2028-01-31
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT06450171

The ClinicalTrials.gov registry entry for NCT06450171 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cancer Predisposition Syndrome appearing as the primary indexed condition, and to 1 intervention - of which GRAIL Galleri Test is the first listed.

NCT06450171 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06450171 about?

NCT06450171 is a clinical study titled "Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study". The purpose of this research study is to evaluate the possible benefits and harms of screening with an investigational blood test designed to detect many types of cancer early. The name of the screening blood test being studied is: -GRAIL Galleri test

What is the current status of trial NCT06450171?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2024-09-27. Estimated completion is 2028-01-31.

What conditions does trial NCT06450171 study?

This clinical trial studies the following conditions: Cancer Predisposition Syndrome, Predisposition, Genetic.

What interventions are being tested in trial NCT06450171?

The interventions under investigation include: GRAIL Galleri Test (OTHER).

Who is sponsoring clinical trial NCT06450171?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06450171 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer Predisposition Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.